Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Outcomes in patients ≥ 80 years with a diagnosis of a hepatopancreaticobiliary (HPB) malignancy.

Lewis AR, Cipriano C, Wang X, Ward R, Fitzpatrick A, Scott ARM, Rashed A, Raja H, Lamarca A, Hubner RA, Valle JW, McNamara MG.

Med Oncol. 2019 Sep 6;36(10):85. doi: 10.1007/s12032-019-1310-0.

PMID:
31493088
2.

Duodenal neuroendocrine tumour associated with minimal change glomerulonephritis.

Montague E, Hockenhull K, Lamarca A, Al-Sayed T, Hubner RA.

BMJ Case Rep. 2019 Aug 30;12(8). pii: e227987. doi: 10.1136/bcr-2018-227987.

PMID:
31473631
3.

Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer.

Mohan S, Ayub M, Rothwell DG, Gulati S, Kilerci B, Hollebecque A, Sun Leong H, Smith NK, Sahoo S, Descamps T, Zhou C, Hubner RA, McNamara MG, Lamarca A, Valle JW, Dive C, Brady G.

Sci Rep. 2019 Aug 12;9(1):11610. doi: 10.1038/s41598-019-47489-7.

4.

Resolution of necrolytic migratory erythema with somatostatin analogue in a patient diagnosed with pancreatic glucagonoma.

Saavedra C, Lamarca A, Hubner RA.

BMJ Case Rep. 2019 Aug 10;12(8). pii: e229115. doi: 10.1136/bcr-2018-229115.

PMID:
31401568
5.

Advanced intrahepatic cholangiocarcinoma: post-hoc analysis of the ABC-01, -02 and -03 clinical trials.

Lamarca A, Ross P, Wasan HS, Hubner RA, McNamara MG, Lopes A, Manoharan P, Palmer D, Bridgewater J, Valle JW.

J Natl Cancer Inst. 2019 May 11. pii: djz071. doi: 10.1093/jnci/djz071. [Epub ahead of print]

PMID:
31077311
6.

Adjuvant chemotherapy and outcomes in patients with nodal and resection margin-negative pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.

Flaum N, Hubner RA, Valle JW, Amir E, McNamara MG.

J Surg Oncol. 2019 Jun;119(7):932-940. doi: 10.1002/jso.25440. Epub 2019 Mar 5.

PMID:
30838647
7.

18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) for patients with biliary tract cancer: Systematic review and meta-analysis.

Lamarca A, Barriuso J, Chander A, McNamara MG, Hubner RA, ÓReilly D, Manoharan P, Valle JW.

J Hepatol. 2019 Jul;71(1):115-129. doi: 10.1016/j.jhep.2019.01.038. Epub 2019 Feb 21.

PMID:
30797051
8.

Identification of patients with pancreatic adenocarcinoma due to inheritable mutation: Challenges of daily clinical practice.

Fulton AJ, Lamarca A, Nuttall C, McCallum L, Pihlak R, O'Reilly D, Lalloo F, McNamara MG, Hubner RA, Clancy T, Valle JW.

World J Gastrointest Oncol. 2019 Feb 15;11(2):102-116. doi: 10.4251/wjgo.v11.i2.102.

9.

Carboplatin in Combination with Oral or Intravenous Etoposide for Extra-Pulmonary, Poorly-Differentiated Neuroendocrine Carcinomas.

Frizziero M, Spada F, Lamarca A, Kordatou Z, Barriuso J, Nuttall C, McNamara MG, Hubner RA, Mansoor W, Manoharan P, Fazio N, Valle JW.

Neuroendocrinology. 2019;109(2):100-112. doi: 10.1159/000497336. Epub 2019 Jan 21.

PMID:
30703770
10.

NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.

Wang-Gillam A, Hubner RA, Siveke JT, Von Hoff DD, Belanger B, de Jong FA, Mirakhur B, Chen LT.

Eur J Cancer. 2019 Feb;108:78-87. doi: 10.1016/j.ejca.2018.12.007. Epub 2019 Jan 14.

11.

Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe.

Javed MA, Beyer G, Le N, Vinci A, Wong H, Palmer D, Morgan RD, Lamarca A, Hubner RA, Valle JW, Alam S, Chowdhury S, Ma YT, Archibugi L, Capurso G, Maisonneuve P, Neesse A, Sund M, Schober M, Krug S.

Pancreatology. 2019 Jan;19(1):97-104. doi: 10.1016/j.pan.2018.10.003. Epub 2018 Oct 15.

PMID:
30529068
12.

Urgent need for consensus: international survey of clinical practice exploring use of platinum-etoposide chemotherapy for advanced extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC).

Lamarca A, Frizziero M, Barriuso J, McNamara MG, Hubner RA, Valle JW.

Clin Transl Oncol. 2019 Jul;21(7):950-953. doi: 10.1007/s12094-018-1996-z. Epub 2018 Nov 30.

PMID:
30506132
13.

Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin.

Hubner RA, Cubillo A, Blanc JF, Melisi D, Von Hoff DD, Wang-Gillam A, Chen LT, Becker C, Mamlouk K, Belanger B, Yang Y, de Jong FA, Siveke JT.

Eur J Cancer. 2019 Jan;106:24-33. doi: 10.1016/j.ejca.2018.09.029. Epub 2018 Nov 17.

14.

Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial.

Chen LT, Siveke JT, Wang-Gillam A, Li CP, Bodoky G, Dean AP, Shan YS, Jameson GS, Macarulla T, Lee KH, Cunningham D, Blanc JF, Chiu CF, Schwartsmann G, Braiteh FS, Mamlouk K, Belanger B, de Jong FA, Hubner RA.

Eur J Cancer. 2018 Dec;105:71-78. doi: 10.1016/j.ejca.2018.09.010. Epub 2018 Nov 8.

15.

Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis.

McNamara MG, Slagter AE, Nuttall C, Frizziero M, Pihlak R, Lamarca A, Tariq N, Valle JW, Hubner RA, Knox JJ, Amir E.

Eur J Cancer. 2018 Dec;105:1-9. doi: 10.1016/j.ejca.2018.09.031. Epub 2018 Oct 29.

PMID:
30384012
16.

The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers.

Lamarca A, Galdy S, Barriuso J, Moghadam S, Beckett E, Rogan J, Backen A, Billington C, McNamara MG, Hubner RA, Cramer A, Valle JW.

PLoS One. 2018 Oct 18;13(10):e0206007. doi: 10.1371/journal.pone.0206007. eCollection 2018. Erratum in: PLoS One. 2019 Feb 15;14(2):e0212697.

17.

Somatostatin analogue-induced pancreatic exocrine insufficiency in patients with neuroendocrine tumors: results of a prospective observational study.

Lamarca A, McCallum L, Nuttall C, Barriuso J, Backen A, Frizziero M, Leon R, Mansoor W, McNamara MG, Hubner RA, Valle JW.

Expert Rev Gastroenterol Hepatol. 2018 Jul;12(7):723-731. doi: 10.1080/17474124.2018.1489232. Epub 2018 Jun 28.

PMID:
29923433
18.

Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma.

Abou-Alfa GK, Qin S, Ryoo BY, Lu SN, Yen CJ, Feng YH, Lim HY, Izzo F, Colombo M, Sarker D, Bolondi L, Vaccaro G, Harris WP, Chen Z, Hubner RA, Meyer T, Sun W, Harding JJ, Hollywood EM, Ma J, Wan PJ, Ly M, Bomalaski J, Johnston A, Lin CC, Chao Y, Chen LT.

Ann Oncol. 2018 Jun 1;29(6):1402-1408. doi: 10.1093/annonc/mdy101.

PMID:
29659672
19.

PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours.

Lamarca A, Nonaka D, Breitwieser W, Ashton G, Barriuso J, McNamara MG, Moghadam S, Rogan J, Mansoor W, Hubner RA, Clark C, Chakrabarty B, Valle JW.

Oncotarget. 2018 Feb 12;9(19):14922-14938. doi: 10.18632/oncotarget.24464. eCollection 2018 Mar 13.

20.

Update on Treatment Options for Advanced Bile Duct Tumours: Radioembolisation for Advanced Cholangiocarcinoma.

Najran P, Lamarca A, Mullan D, McNamara MG, Westwood T, Hubner RA, Lawrence J, Manoharan P, Bell J, Valle JW.

Curr Oncol Rep. 2017 Jul;19(7):50. doi: 10.1007/s11912-017-0603-8. Review.

21.

Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.

Meyer T, Fox R, Ma YT, Ross PJ, James MW, Sturgess R, Stubbs C, Stocken DD, Wall L, Watkinson A, Hacking N, Evans TRJ, Collins P, Hubner RA, Cunningham D, Primrose JN, Johnson PJ, Palmer DH.

Lancet Gastroenterol Hepatol. 2017 Aug;2(8):565-575. doi: 10.1016/S2468-1253(17)30156-5. Epub 2017 Jun 23. Erratum in: Lancet Gastroenterol Hepatol. 2017 Sep;2(9):e6.

22.

A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C.

Almhanna K, Wright D, Mercade TM, Van Laethem JL, Gracian AC, Guillen-Ponce C, Faris J, Lopez CM, Hubner RA, Bendell J, Bols A, Feliu J, Starling N, Enzinger P, Mahalingham D, Messersmith W, Yang H, Fasanmade A, Danaee H, Kalebic T.

Invest New Drugs. 2017 Oct;35(5):634-641. doi: 10.1007/s10637-017-0473-9. Epub 2017 May 19.

PMID:
28527133
23.

The dark side of T1 non-appendiceal small bowel neuroendocrine tumors.

Salih Z, Lamarca A, Nonaka D, Hubner RA, de Liguori-Carino N, McNamara MG, Fulford P, Minicozzi A, O'Dwyer S, Chakrabarty B, Valle JW.

Hum Pathol. 2017 Aug;66:239-240. doi: 10.1016/j.humpath.2017.02.030. Epub 2017 May 9. No abstract available.

PMID:
28499547
24.

Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.

Chiramel J, Backen AC, Pihlak R, Lamarca A, Frizziero M, Tariq NU, Hubner RA, Valle JW, Amir E, McNamara MG.

Int J Mol Sci. 2017 Apr 26;18(5). pii: E909. doi: 10.3390/ijms18050909. Review.

25.

Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis.

Pelzer U, Blanc JF, Melisi D, Cubillo A, Von Hoff DD, Wang-Gillam A, Chen LT, Siveke JT, Wan Y, Solem CT, Botteman MF, Yang Y, de Jong FA, Hubner RA.

Br J Cancer. 2017 May 9;116(10):1247-1253. doi: 10.1038/bjc.2017.67. Epub 2017 Mar 28.

26.

Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C.

Almhanna K, Miron ML, Wright D, Gracian AC, Hubner RA, Van Laethem JL, López CM, Alsina M, Muñoz FL, Bendell J, Firdaus I, Messersmith W, Ye Z, Fasanmade AA, Danaee H, Kalebic T.

Invest New Drugs. 2017 Apr;35(2):235-241. doi: 10.1007/s10637-017-0439-y. Epub 2017 Feb 11.

PMID:
28188407
27.

Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients With High-Grade Gastrointestinal Neuroendocrine Carcinomas.

Lamarca A, Walter T, Pavel M, Borbath I, Freis P, Nuñez B, Childs A, McNamara MG, Hubner RA, Garcia-Carbonero R, Meyer T, Valle JW, Barriuso J.

J Natl Cancer Inst. 2017 Jan 27;109(5). doi: 10.1093/jnci/djw277. Print 2017 Jan.

PMID:
28130474
28.

Elderly patients diagnosed with hepatopancreatobiliary malignancies: A challenge beyond resection.

Lamarca A, Pihlak R, Frizziero M, McNamara MG, Hubner RA, Valle JW.

Cancer. 2017 Mar 1;123(5):888-890. doi: 10.1002/cncr.30502. Epub 2017 Jan 6. No abstract available.

29.

HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?

Galdy S, Lamarca A, McNamara MG, Hubner RA, Cella CA, Fazio N, Valle JW.

Cancer Metastasis Rev. 2017 Mar;36(1):141-157. doi: 10.1007/s10555-016-9645-x. Review.

30.

Sorafenib for the Treatment of Advanced Hepatocellular Cancer - a UK Audit.

King J, Palmer DH, Johnson P, Ross P, Hubner RA, Sumpter K, Darby S, Braconi C, Iwuji C, Swinson D, Collins P, Patel K, Nobes J, Muazzam I, Blesing C, Kirkwood A, Nash S, Meyer T.

Clin Oncol (R Coll Radiol). 2017 Apr;29(4):256-262. doi: 10.1016/j.clon.2016.11.012. Epub 2016 Dec 10.

PMID:
27964898
31.

Telotristat ethyl: a new option for the management of carcinoid syndrome.

Lamarca A, Barriuso J, McNamara MG, Hubner RA, Valle JW.

Expert Opin Pharmacother. 2016 Dec;17(18):2487-2498. Epub 2016 Nov 16. Review.

PMID:
27817224
32.

Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens.

Vogel A, Ciardiello F, Hubner RA, Blanc JF, Carrato A, Yang Y, Patel DA, Ektare V, de Jong FA, Gill S.

Cancer Treat Rev. 2016 Nov;50:142-147. doi: 10.1016/j.ctrv.2016.09.001. Epub 2016 Sep 9. Review.

PMID:
27676174
33.

Prognostic factors for disease relapse in patients with neuroendocrine tumours who underwent curative surgery.

Slagter AE, Ryder D, Chakrabarty B, Lamarca A, Hubner RA, Mansoor W, O'Reilly DA, Fulford PE, Klümpen HJ, Valle JW, McNamara MG.

Surg Oncol. 2016 Sep;25(3):223-8. doi: 10.1016/j.suronc.2016.05.019. Epub 2016 May 26.

PMID:
27566026
34.

Identification of clinical biomarkers for patients with advanced hepatocellular carcinoma receiving sorafenib.

Lamarca A, Abdel-Rahman O, Salu I, McNamara MG, Valle JW, Hubner RA.

Clin Transl Oncol. 2017 Mar;19(3):364-372. doi: 10.1007/s12094-016-1537-6. Epub 2016 Aug 19.

PMID:
27541594
35.

Impact of biliary stent-related events in patients diagnosed with advanced pancreatobiliary tumours receiving palliative chemotherapy.

Lamarca A, Rigby C, McNamara MG, Hubner RA, Valle JW.

World J Gastroenterol. 2016 Jul 14;22(26):6065-75. doi: 10.3748/wjg.v22.i26.6065.

36.

A multicentre comparison between Child Pugh and Albumin-Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma.

Edeline J, Blanc JF, Johnson P, Campillo-Gimenez B, Ross P, Ma YT, King J, Hubner RA, Sumpter K, Darby S, Evans J, Iwuji C, Swinson D, Collins P, Patel K, Muazzam I, Palmer DH, Meyer T.

Liver Int. 2016 Dec;36(12):1821-1828. doi: 10.1111/liv.13170. Epub 2016 Jun 22.

PMID:
27214151
37.

A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours.

Fazio N, Buzzoni R, Baudin E, Antonuzzo L, Hubner RA, Lahner H, DE Herder WW, Raderer M, Teulé A, Capdevila J, Libutti SK, Kulke MH, Shah M, Dey D, Turri S, Aimone P, Massacesi C, Verslype C.

Anticancer Res. 2016 Feb;36(2):713-9.

38.

"If You Prick Us, Do We Not Bleed?" Whom Should We Choose?

McNamara MG, Lamarca A, Hubner RA, Valle JW.

J Clin Oncol. 2016 Feb 10;34(5):513-4. doi: 10.1200/JCO.2015.63.4576. Epub 2016 Jan 4. No abstract available.

PMID:
26729429
39.

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.

Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT; NAPOLI-1 Study Group.

Lancet. 2016 Feb 6;387(10018):545-557. doi: 10.1016/S0140-6736(15)00986-1. Epub 2015 Nov 29. Erratum in: Lancet. 2016 Feb 6;387(10018):536.

PMID:
26615328
40.

Routine measurement of plasma chromogranin B has limited clinical utility in the management of patients with neuroendocrine tumours.

Monaghan PJ, Lamarca A, Valle JW, Hubner RA, Mansoor W, Trainer PJ, Darby D.

Clin Endocrinol (Oxf). 2016 Mar;84(3):348-52. doi: 10.1111/cen.12985. Epub 2015 Dec 24.

PMID:
26608723
41.

Appendiceal Goblet Cell Carcinoids: Management Considerations from a Reference Peritoneal Tumour Service Centre and ENETS Centre of Excellence.

Lamarca A, Nonaka D, Lopez Escola C, Hubner RA, O'Dwyer S, Chakrabarty B, Fulford P, Valle JW.

Neuroendocrinology. 2016;103(5):500-17. doi: 10.1159/000440725. Epub 2015 Sep 10.

PMID:
26356507
42.

To BRCA or Not to PALB.

McNamara MG, Lamarca A, Hubner RA, Valle JW.

J Clin Oncol. 2015 Aug 10;33(23):2581-2. doi: 10.1200/JCO.2014.60.0585. Epub 2015 Jun 29. No abstract available.

PMID:
26124473
43.

Angioleiomyoma of the nasal cavity.

Arruda MM, Monteiro DY, Fernandes AM, Menegatti V, Thomazzi E, Hubner RA, Lima LG.

Int Arch Otorhinolaryngol. 2014 Oct;18(4):409-11. doi: 10.1055/s-0033-1364173. Epub 2014 Jan 21.

44.

Somatostatin receptor expression in hepatocellular carcinoma: prognostic and therapeutic considerations.

Abdel-Rahman O, Lamarca A, Valle JW, Hubner RA.

Endocr Relat Cancer. 2014;21(6):R485-93. doi: 10.1530/ERC-14-0389. Epub 2014 Oct 21. Review.

PMID:
25336571
45.

Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors.

Valle JW, Faivre S, Hubner RA, Grande E, Raymond E.

Cancer Treat Rev. 2014 Dec;40(10):1230-8. doi: 10.1016/j.ctrv.2014.09.001. Epub 2014 Sep 16.

46.

Reply to the letter to the editor 'second-line chemotherapy in advanced biliary cancer: the present now will later be past' by Vivaldi et al.

Lamarca A, Hubner RA, Ryder WD, Valle JW.

Ann Oncol. 2014 Dec;25(12):2444-5. doi: 10.1093/annonc/mdu382. Epub 2014 Aug 19. No abstract available.

PMID:
25139549
47.

Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial.

Dutton SJ, Ferry DR, Blazeby JM, Abbas H, Dahle-Smith A, Mansoor W, Thompson J, Harrison M, Chatterjee A, Falk S, Garcia-Alonso A, Fyfe DW, Hubner RA, Gamble T, Peachey L, Davoudianfar M, Pearson SR, Julier P, Jankowski J, Kerr R, Petty RD.

Lancet Oncol. 2014 Jul;15(8):894-904. doi: 10.1016/S1470-2045(14)70024-5. Epub 2014 Jun 17.

PMID:
24950987
48.

Second-line chemotherapy in advanced biliary cancer: a systematic review.

Lamarca A, Hubner RA, David Ryder W, Valle JW.

Ann Oncol. 2014 Dec;25(12):2328-38. doi: 10.1093/annonc/mdu162. Epub 2014 Apr 25. Review.

PMID:
24769639
49.

Gemcitabine plus capecitabine in unselected patients with advanced pancreatic cancer.

Hubner RA, Worsnop F, Cunningham D, Chau I.

Pancreas. 2013 Apr;42(3):511-5. doi: 10.1097/MPA.0b013e31826c6aee.

PMID:
23462324
50.

Sunitinib for advanced pancreatic neuroendocrine tumors.

Hubner RA, Valle JW.

Expert Rev Anticancer Ther. 2011 Dec;11(12):1817-27. doi: 10.1586/era.11.171. Review.

PMID:
22117148

Supplemental Content

Loading ...
Support Center